title: Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome.
abstract: Sacral neuromodulation (SNM) is a guideline-recommended third-line treatment option for managing overactive bladder. Current SNM devices are not rechargeable, and require neurostimulator replacement every 3-6 years. Our study objective was to assess potential cost effects to payers of adopting a rechargeable SNM neurostimulator device.
  
  
  
  We constructed a cost-consequence model to estimate the costs of long-term SNM-treatment with a rechargeable versus non-rechargeable device. Costs were considered from the payer perspective at 2015 reimbursement levels. Adverse events, therapy discontinuation, and programming rates were based on the latest published data. Neurostimulator longevity was assumed to be 4.4 and 10.0 years for non-rechargeable and rechargeable devices, respectively. A 15-year horizon was modeled, with costs discounted at 3% per year. Total budget impact to the United States healthcare system was estimated based on the computed per-patient cost findings.
  
  
  
  Over the 15-year horizon, per-patient cost of treatment with a non-rechargeable device was $64,111 versus $36,990 with a rechargeable device, resulting in estimated payer cost savings of $27,121. These cost savings were found to be robust across a wide range of scenarios. Longer analysis horizon, younger patient age, and longer rechargeable neurostimulator lifetime were associated with increased cost savings. Over a 15-year horizon, adoption of a rechargeable device strategy was projected to save the United States healthcare system up to $12 billion.
  
  
  
  At current reimbursement rates, our analysis suggests that rechargeable neurostimulator SNM technology for managing overactive bladder syndrome may deliver significant cost savings to payers over the course of treatment. Neurourol. Urodynam. 36:727-733, 2017. © 2016 Wiley Periodicals, Inc.
authors.affiliation: University of California, Riverside, California.
authors.forename: Karen L
authors.initials: KL
authors.lastname: Noblett
authors.affiliation: Vanderbilt University, Nashville, Tennessee.
authors.forename: Roger R
authors.initials: RR
authors.lastname: Dmochowski
authors.affiliation: Cleveland Clinic, Cleveland, Ohio.
authors.forename: Sandip P
authors.initials: SP
authors.lastname: Vasavada
authors.affiliation: Wing Tech, Inc., Menlo Park, California.
authors.forename: Abigail M
authors.initials: AM
authors.lastname: Garner
authors.affiliation: Wing Tech, Inc., Menlo Park, California.|University of Washington, Seattle, Washington.
authors.forename: Shan
authors.initials: S
authors.lastname: Liu
authors.affiliation: Wing Tech, Inc., Menlo Park, California.
authors.forename: Jan B
authors.initials: JB
authors.lastname: Pietzsch
mesh_terms: D003365:Costs and Cost Analysis; D004599:Electric Stimulation Therapy / Q000191:economics* / Q000295:instrumentation; D006801:Humans; D058542:Implantable Neurostimulators / Q000191:economics*; D008962:Models, Theoretical; D012447:Sacrum; D053201:Urinary Bladder, Overactive / Q000191:economics / Q000628:therapy*
keywords: cost analysis; overactive bladder; rechargeable neurostimulator; sacral neuromodulation